Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Date:3/19/2013

CRANBURY, N.J., March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914 (the '914 application).  The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides.

Palatin is conducting in vitro and animal in vivo studies with the peptides claimed in the allowed patent and with related peptides.  Proposed indications under study include dermatologic indications such as vitiligo and erythropoietic protoporphyria, inflammatory bowel disease, ocular indications such as uveitis and dry eye, and nephritis and other kidney conditions.  Palatin plans to designate an initial clinical lead peptide candidate in the first half of 2013 and start toxicology and other preclinical studies preparatory to filing an Investigational New Drug Application with the U.S. Food and Drug Administration.

The peptides claimed in the '914 application are highly specific for the melanocortin-1 receptor, with sub-nanomolar affinity binding and EC50 functional values.  The peptides are also highly selective for the melanocortin-1 receptor, with greater than one thousand times the affinity for the melanocortin-1 receptor than for the melanocortin-4 or melanocortin-3 receptors.

"We are excited by the potential of our novel melanocortin receptor-1 peptides," stated Carl Spana , Ph.D., President and CEO of Palatin. "There are a number of significant unmet medical needs for which our highly specific and selective peptides can potentially provide new therapies."

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030.  The 13/472,914 Notice of Allowance has been posted on the USPTO public PAIR website. 

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about potential clinical utility of melanocortin receptor-1 peptides, whether the subject patent will issue or adequately protect against competition, the future status of pending and planned patent applications, potential clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for melanocortin receptor-1 peptide product candidates and market potential for melanocortin receptor-1 peptide product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Patient Safety Technologies Reports Fourth Quarter And Fiscal 2012 Results
3. Medbox Acquires 50% of MedVend and its Patented Technologies
4. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
5. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
6. Xyntek-Antares & ESS Technologies to Unveil New Ultra Compact TaskMate(R) Robotic Case Erector / Loader with Track & Trace at Interphex 2013
7. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
8. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
11. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... March 27, ... ... U.S. drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 ... Assemblyman Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... the RealSelf 100 Award, a prestigious award honoring the top influencers on RealSelf—the ... find and connect with doctors and clinics. , In 2016, more than 82 ...
(Date:3/24/2017)... ... 2017 , ... Clean Earth, Inc., a leader in providing ... materials announced today the acquisition of privately owned AERC Recycling Solutions ... facilities and a vast array of additional technologies, services, and new markets to ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
Breaking Medicine News(10 mins):